Ikonisys Inc.
This article was originally published in Start Up
Executive Summary
Two-year-old Ikonisys has developed a cell-based analysis system for detecting rare cells in blood. Its first application is detection of fetal cells in maternal blood, a longstanding ambition of many companies, none of which has succeeded to date. The test would detect the most common birth defects earlier in a pregnancy and more accurately than existing methods. Ikonisys also sees a big opportunity in cancer for early detection of disease and micrometastasis.